Key Decisions

1
Key Decisions Actions

• Donor Committee Meeting
• Seattle, 9 November 2007

2
AMC Pilots Objectives

• The AMC Pilot seeks to accelerate the
  introduction of a pneumo vaccine to save lives by
  achieving the following
• increased private sector investment (including
  new manufacturing facilities)
• accelerated uptake, and
• sustainable vaccine price.

3
Economic Expert Group Recommendations Adopted by
DC

• EE Group Recommendation 1
• The AMC should be integrated into the GAVI
  process to finance new vaccines, for the
  following four reasons
• Multiple countries will be procuring vaccines
  an intermediary is needed to work with the firms
  to simplify the process.
• Integrating the AMC into GAVI will provide
  companies with some assurance that post-AMC
  financing exists.
• Countries will have a different ability to pay,
  and GAVI has a mechanism to address these
  differences.
• The AMC process should be transparent and aligned
  with other vaccine processes (including future
  AMCs).
• EE Group Recommendation 2
• The tail price should be integrated with the
  country co-pay.

4
Economic Expert Group EE and DC Actions

• Actions
• The EE group will meet In London (Nov 19-20) to
  reach closure on key recommendations and work on
  their draft report, which is due by the end of
  December.
• Before finalizing report, the EE group will send
  the DC an interim issues paper for their review
  and comment.
• The DC chair will work with GAVI to coordinate a
  workshop for the DC and the EE group to discuss
  key issues and recommendations before EE report
  is finalized.

5
Economic Expert Group DiscussionGAVI Actions

• Since financing for vaccines during both the AMC
  period and the tail price period will come from
  GAVI, the AMC will have implications for GAVIs
  operations.
• Actions
• GAVI to present AMC rationale and importance to
  GAVI board as well as preliminary implications
  for GAVI administration and organization.
• GAVI to continue discussions with their Audit and
  Finance Committee regarding balance sheet risk
  from AMC and pursue Committee decision in
  February.

6
Monitoring Evaluation Group Actions

• The final report of the ME group will be
  completed by November 24.
• Action
• The DC will discuss AMC goals and objectives and
  comment on the AMC Secretariat TOR on next DC
  teleconference.

7
Communications Group

• The DC expressed strong interest in strengthening
  the communication plan and moving from a reactive
  to a proactive stance. The DC wants there to be
  very clear messaging about AMCs, including strong
  support from developing country voices.
• The donor envelope is fixed at 1.5 billion.
  Additional contributions are welcome but would
  reduce the total obligations for existing donors
  rather than increase the envelope.

8
Communications Group Actions

• Actions
• Donors to send feedback to GAVI on communications
  materials and, if possible, to identify donor
  communications staff who might be able to help
  out with AMC messaging.
• The Communications Group will convene before the
  end of November to draft an implementation plan
  indicating key activities and responsibilities in
  communications.
• Communications Group members will report back to
  the US NGO advocacy group.

9
Legal Group Actions

• The AMC Secretariat is not a decision making
  body.
• IAC has decision-making authority, and IACs
  decisions are final.
• The IAC will not be hosted within WHO.
• Actions
• The Legal Group will review DC comments and
  questions, including
• Changing IAC charter and bylaws
• IAC ability to amend legal agreements (e.g. TPP)
• The DC will provide feedback to the legal
  documents.

10
Financing Update

• The Financing committee approved the balance
  sheet proposal. The next meeting will be a joint
  Audit and Code meeting where the focus will be on
  financial and organizational risk assessments.
  The board meeting is tentatively scheduled for
  early January.

11
Procurement Update

• GAVI is waiting for UNICEFs decision (with an
  Oct 31 deadline) about whether UNICEF will adapt
  their systems to accommodate the procurement
  requirements of AMCs, which include
• up front price for all manufacturers
• lower tail price once the AMC is exhausted
• countries choose among different products made
• The DC agreed on the importance of raising this
  issue with senior UNICEF management. DC asked
  GAVI to contact UNICEF again, requesting a
  decision before GAVIs Board meeting (Nov 26-28).

12
ProcurementActions

• Actions
• GAVI will provide contact names and core script
  to the DC with key messages to relay to UNICEF.
• Canada, UK, and BMGF agreed to raise issues with
  Ann Veneman.
• GAVI will contact UNICEF to offer new deadline.
• GAVI will send resolution to Board members two
  weeks before the Board meeting requesting support
  to circulate an RFP to procure vaccines for AMC
  if UNICEF does not respond by Board meeting
  deadline.

13
WorkplanActions

• Actions
• GAVI will circulate an updated workplan with an
  end of February timeline to the DC. GAVI will
  highlight the 3-4 potential obstacles that could
  push the timeline back.
• The UK and the Canada have views about GAVI donor
  governance and will put together an options paper
  that reflects these ideas to share with the DC.